Industry
Biotechnology
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
February 26, 2024 | 5:07 pm
Portfolio Pulse from Avi Kapoor
February 20, 2024 | 6:21 pm
Portfolio Pulse from Benzinga Insights
February 20, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
February 08, 2024 | 1:04 pm
Portfolio Pulse from Avi Kapoor
January 22, 2024 | 6:08 pm
Portfolio Pulse from Benzinga Insights
January 19, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
December 19, 2023 | 5:32 pm
Portfolio Pulse from Benzinga Newsdesk
November 30, 2023 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
November 08, 2023 | 10:17 pm
Portfolio Pulse from Benzinga Newsdesk
October 26, 2023 | 12:36 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.